Citadel Advisors
HCWB icon

Citadel Advisors’s HCW Biologics HCWB Stock Holding History

Citadel Advisors’s Portfolio HCWB Stock Details HCWB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$99.5K Buy
19,942
+15,595
+359% +$88.4K ﹤0.01% 12704
2026
Q1 		$9.39K Buy
4,347
+654
+18% +$3.38K ﹤0.01% 12770
2025
Q4 		$21.5K Buy
+3,693
New +$62.8K ﹤0.01% 12328
2024
Q3 		– Sell
-58
Closed -$8.98K – 14618
2024
Q2 		$8.98K Buy
+58
New +$17.1K ﹤0.01% 13158
2024
Q1 		– Sell
-43
Closed -$12.7K – 14919
2023
Q4 		$12.7K Buy
+43
New +$14.7K ﹤0.01% 12979

Other funds holding HCWB

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GSWM
Golden State Wealth Management Santa Ana, California $1.1B AUM 27.5% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Citadel Advisors's HCWB Position: Q2 2026 in Review

Citadel Advisors increased its HCW Biologics (HCWB) stake by 359% in Q2 2026, buying an estimated $88.4K and bringing the position to 19,942 shares worth $99.5K. The position accounts for ﹤0.01% of the portfolio, ranked #12704.

Citadel Advisors first reported a position in HCWB in Q4 2023 and has held it in 5 quarters since. 12 funds tracked by Wall St. Rank hold HCWB as of Q2 2026.

  • Citadel Advisors held 19,942 shares of HCW Biologics worth $99.5K as of Q2 2026.
  • Citadel Advisors bought 15,595 HCW Biologics shares in Q2 2026, an estimated $88.4K.
  • HCW Biologics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12704 holding.
  • Citadel Advisors first reported a position in HCW Biologics in Q4 2023 and has held it in 5 quarters since.
  • 12 funds tracked by Wall St. Rank held HCW Biologics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.